Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
基本信息
- 批准号:10384769
- 负责人:
- 金额:$ 59.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:AdhesivesBiocompatible MaterialsBiological MarkersBiomedical EngineeringBloodBlood BanksBlood PlateletsCathetersChemicalsChronicClinicClinicalCollaborationsColonColorectalComplexCoupledDataEngineeringEnsureEnteralEnterocutaneous FistulaExtravasationFailureFamily suidaeFecesFibrinFistulaFluoroscopyFormulationGelGrowth FactorHealth Care CostsHistologyHydrogelsImageImaging technologyIn VitroIncontinenceInfectionInflammationInjectableIntensive Care UnitsInterventionInterventional ImagingIntestinesIrritantsLeadLiteratureMagnetic Resonance ImagingMalnutritionMedicalMental DepressionModelingMorbidity - disease rateMorphologic artifactsNeckOperative Surgical ProceduresOrganOutcome MeasurePainPancreatic enzymePatientsPeptide HydrolasesPerformancePopulationPostoperative PeriodPre-Clinical ModelPredispositionPropertyProteinsPusQuality of lifeRNARadiationRattusRecurrenceRodentRoentgen RaysSkinSlideSmall IntestinesStomach ContentSurgeonSurgical complicationTechniquesTestingTherapeutic EffectThinnessTimeTissuesTreatment EfficacyVisitX-Ray Computed TomographyX-Ray Medical Imagingadhesive polymeranimal dataantimicrobialbasebiomaterial compatibilityfollow-uphealingimage guidedimplantationimprovedin vitro testingin vivoin vivo Modelmechanical propertiesmicroCTminimally invasivemortalitypreventprogramsregenerativesealskillssubcutaneoustranscriptome sequencingultrasoundwound care
项目摘要
Abstract
Enterocutaneous fistula (ECF) is an abnormal connection between the bowel and skin. It can be associated with
discharge of pus, feces, and stomach contents and can even lead to incontinence. ECFs are referred to as
surgical tragedies in the literature, as up to 85% are the result of intraabdominal surgical complications, such as
missed enterotomies or anastomotic leaks. This can lead to constant leakage of enteric and fecal contents from
the skin, sometimes up to many liters per day. The foul enteric contents act as a chemical irritant to the skin,
leading to skin breakdown and predisposition to infection. Despite advances in treatment, ECFs still account for
significant mortality of 15-20% and are associated with debilitating morbidity and substantially poor quality of life
due to complex wound care, severe malnutrition, frequent infectious complications, pain, and depression.
Despite advances in surgical techniques and postoperative management, no successful treatment of ECF exists
today. The current treatment paradigm is unsuccessful; high fistula discharge, infection, and chronic
inflammation lead to high failure and recurrence rates. This often results in prolonged intensive care unit (ICU)
stays increasing health care cost which can be over $500,000 per ICU visit. We hypothesize that by using a
bioengineered biomaterial that is biocompatible, non-toxic, durable, antimicrobial and regenerative, we would
change the standard of medical practice in the approach to ECF. This creative approach may reduce world-wide
morbidity and mortality by successfully occluding and healing any ECF, preventing fecal leakage; it will also
substantially improve the quality of life of the patient and reduce the need for repeated interventions and X-ray
imaging. We aim to make a paradigm shift in the treatment of potentially fatal ECF using a minimally invasive
blood-derived biomaterial-based platform to occlude the fistulous tract using groundbreaking injectable shear-
thinning platelet-rich gels. We will engineer the blood derived biomaterial to include antimicrobial, adhesive, and
regenerative components that will be tested in vitro and in vivo (Aim 1) and we will evaluate the optimized
biomaterial with established rodent fistula models (Aim 2). Finally, we will test theses engineered biomaterials in
a porcine ECF model to promote aseptic healing of fistulas (Aim 3). We will evaluate healing trajectories of the
fistulas using clinical observation, fluoroscopy, ultrasound, micro-CT, histology, Helios mass cytometer analysis
of the cellular populations and the Hyperion imaging technology to evaluate up to 37 biomarkers on slides and
RNA sequencing.
摘要
肠外瘘(ECF)是肠道和皮肤之间的异常连接。可关联
排出脓液、粪便和胃内容物,甚至可能导致失禁。ECF被称为
文献中的手术悲剧,高达85%是腹腔内手术并发症的结果,如
漏行肠切开术或吻合口漏这可能导致肠和粪便内容物不断泄漏,
皮肤,有时每天高达许多升。肠内的污秽物对皮肤有化学刺激作用,
导致皮肤破裂和易受感染。尽管治疗取得了进展,ECFs仍然占
显著死亡率为15-20%,并与虚弱的发病率和实质上较差的生活质量相关
由于复杂的伤口护理、严重的营养不良、频繁的感染并发症、疼痛和抑郁。
尽管外科技术和术后管理的进步,ECF的成功治疗还不存在
今天目前的治疗模式是不成功的;高瘘分泌物,感染,和慢性
炎症导致高失败率和复发率。这往往导致长期重症监护病房(ICU)
这会增加医疗保健成本,每次ICU就诊可能超过50万美元。我们假设通过使用
生物工程生物材料是生物相容性,无毒,耐用,抗菌和再生,我们将
改变ECF方法中的医疗实践标准。这种创造性的方法可能会减少世界范围内的
通过成功闭合和治愈任何ECF,防止粪便渗漏,
大大提高患者的生活质量,减少重复干预和X射线的需要
显像我们的目标是在使用微创技术治疗可能致命的ECF方面实现范式转变。
基于血液的生物材料平台,使用开创性的可注射剪切闭合瘘管,
使富含血小板的凝胶变薄我们将设计血液来源的生物材料,包括抗菌剂,粘合剂,
再生组件,将在体外和体内进行测试(目标1),我们将评估优化的
生物材料与已建立的啮齿动物瘘管模型(目的2)。最后,我们将测试这些工程生物材料,
猪ECF模型,以促进瘘管的无菌愈合(目的3)。我们将评估的愈合轨迹的
瘘管采用临床观察、透视、超声、显微CT、组织学、Helios质谱细胞仪分析
细胞群体和生物成像技术,以评估多达37个生物标志物的幻灯片,
RNA测序。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ali Khademhosseini其他文献
Ali Khademhosseini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ali Khademhosseini', 18)}}的其他基金
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
- 批准号:
10397659 - 财政年份:2021
- 资助金额:
$ 59.16万 - 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
- 批准号:
10620134 - 财政年份:2021
- 资助金额:
$ 59.16万 - 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
- 批准号:
10230909 - 财政年份:2021
- 资助金额:
$ 59.16万 - 项目类别:
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
- 批准号:
10532787 - 财政年份:2021
- 资助金额:
$ 59.16万 - 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
- 批准号:
10171610 - 财政年份:2018
- 资助金额:
$ 59.16万 - 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
- 批准号:
9883832 - 财政年份:2018
- 资助金额:
$ 59.16万 - 项目类别:
Engineering personalized micro-tumor ecosystems
设计个性化微肿瘤生态系统
- 批准号:
10261573 - 财政年份:2017
- 资助金额:
$ 59.16万 - 项目类别:
相似海外基金
Photoresponsive, biocompatible materials for reconfigurable intraocular lenses
用于可重构人工晶状体的光响应、生物相容性材料
- 批准号:
DH-2022-00249 - 财政年份:2022
- 资助金额:
$ 59.16万 - 项目类别:
Discovery Horizons
Telemetric mouthguard sensor system with biocompatible materials and MEMS techniques for unconstrained human assessment
采用生物相容性材料和 MEMS 技术的遥测护牙套传感器系统,可实现不受约束的人体评估
- 批准号:
19KK0259 - 财政年份:2019
- 资助金额:
$ 59.16万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
Development of Ion-sensing Membranes Modified Chemically with Biocompatible Materials for Analysis of Biological Samples
开发用于生物样品分析的生物相容性材料化学修饰的离子传感膜
- 批准号:
18K05172 - 财政年份:2018
- 资助金额:
$ 59.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The use of 3D printing techniques in the preparation of biocompatible materials
3D打印技术在生物相容性材料制备中的应用
- 批准号:
1942009 - 财政年份:2017
- 资助金额:
$ 59.16万 - 项目类别:
Studentship
Human periodontal ligament cell adhesions on biocompatible materials
人牙周膜细胞在生物相容性材料上的粘附
- 批准号:
26670892 - 财政年份:2014
- 资助金额:
$ 59.16万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Construction and usage of a mouse or human synthetic lymphoid tissue using biocompatible materials.
使用生物相容性材料构建和使用小鼠或人类合成淋巴组织。
- 批准号:
16590408 - 财政年份:2004
- 资助金额:
$ 59.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DESIGN AND IMPLEMENTATION OF NEW BIOCOMPATIBLE MATERIALS
新型生物相容性材料的设计与实现
- 批准号:
6178836 - 财政年份:2000
- 资助金额:
$ 59.16万 - 项目类别:
DESIGN AND IMPLEMENTATION OF NEW BIOCOMPATIBLE MATERIALS
新型生物相容性材料的设计与实现
- 批准号:
2708568 - 财政年份:1999
- 资助金额:
$ 59.16万 - 项目类别:
DESIGN AND IMPLEMENTATION OF NEW BIOCOMPATIBLE MATERIALS
新型生物相容性材料的设计与实现
- 批准号:
6018399 - 财政年份:1999
- 资助金额:
$ 59.16万 - 项目类别:
Synthesis of Biocompatible Materials Having Blood-Group Antigenic 01 igosaccharide Chain
具有血型抗原01寡糖链的生物相容性材料的合成
- 批准号:
02650662 - 财政年份:1990
- 资助金额:
$ 59.16万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)